Wird geladen...
An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition
Antibodies that target immune checkpoint molecules, such as CTLA4, provide robust antitumor effects in a subset of patients. Unfortunately, not all patients respond to immune checkpoint inhibition, and some develop life-threatening immune-related adverse events (irAEs). The mechanisms that underlie...
Gespeichert in:
| Veröffentlicht in: | J Clin Invest |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society for Clinical Investigation
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6307975/ https://ncbi.nlm.nih.gov/pubmed/30530990 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI125800 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|